ARS PharmaceuticalsSPRY
Recorded

ARS Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration23 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to ARS Pharmaceuticals' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the company's prepared remarks, we will open the line for questions. Please be advised that today's conference is being recorded. I would now like to turn the call over to Monique Allaire, IR representative for the company.

Monique AllaireIR Representative

Please go ahead. Good afternoon, and thank you all for joining us.

Monique AllaireIR Representative

With me on the call today are President and CEO Donn Casale, Chief Commercial Officer Meg Smith, and our Chief Financial Officer Kathy Scott. Earlier today, we issued a press release outlining ARS Pharmaceuticals' commercial highlights and financial results for the third quarter of 2026. That press release can be found in the Investors and Media section of the company's website at ars-pharma.com. Before we begin, please note that today's remarks may contain forward-looking statements, and actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Don.

Donn CasalePresident and CEO

Thank you, Monique, and good afternoon, everyone. In August, I outlined a new strategic direction for ARS and laid out three corporate priorities to build a durable, profitable business. The first is disrupting the legacy epinephrine market with neffy, delivering steady market share gains through targeted provider commercial execution. The second is reaching cash flow breakeven by year-end 2027, based on greater financial discipline that will continue through 2027. The third is expanding our epinephrine delivery platform beyond anaphylaxis and unlocking value with a potential first on-demand treatment of breakthrough flares in chronic spontaneous urticaria, or CSU. I'm very proud of our progress last quarter and the team's execution against each of these priorities. In the third quarter, neffy continued to capture market share, delivering $33.4 million in U.S. net product revenue. Total U.S. market share surpassed 5%, up from 4% in the third quarter of 2025.

Donn CasalePresident and CEO

This was driven by a 42% year-over-year increase in neffy end-user demand. We recorded more than 19,000 unique prescribers in the third quarter, up 49% year-over-year, for a total of nearly 45,000 prescribers since launch. The impact of our commercial execution is even more evident when you look at market share in field-targeted accounts, which represent about 44% of the total market opportunity. Field-targeted share increased from 6% in Q3 last year to 9% in Q3 this year, compared with 2% in non-targeted accounts. So where our field team engages, neffy wins. On our second priority, we have implemented strict financial discipline that we will maintain going forward. Operating expenses in Q3 were in line with the guidance we selected and set last year, reflecting our ongoing commitment to reducing SG&A spend.

Donn CasalePresident and CEO

SG&A expenses in Q3 were down by more than 40% compared to the prior two quarters of this year. Based on our revised expense plan, we reaffirm that we are on track to achieve cash flow breakeven by year-end 2027. Third, on our pipeline, our phase IIb trial with ARS-2 is progressing well, and we expect to report interim data in the first quarter of 2027. An estimated 2 million Americans live with CSU, a debilitating inflammatory condition marked by episodes of severe itch and hives. While biologics have meaningfully improved disease control for many patients, breakthrough flares are common. About 60% of adults remain symptomatic despite taking four times the standard dose of antihistamines, and a third to more than half of patients on approved biologics are not well controlled. There are no FDA-approved therapies indicated to stop a breakthrough flare in progress today.

Donn CasalePresident and CEO

When a severe flare occurs, physicians typically turn to oral corticosteroids, which have side effects that limit their long-term use. This is the opportunity we see for ARS-2, rapid on-demand relief of breakthrough flares rather than another chronic maintenance therapy. Results from our completed phase II trial show ARS-2 improved both itch and hive scores, beginning as early as five minutes after dosing. In our exploratory phase IIb trial, we're evaluating 0.5 milligram and one milligram doses of ARS-2 to identify the minimum effective dose. The trial is progressing, and we're on track to report interim data in the first quarter of 2027. With the interim data, we also plan to share highlights from an ongoing market assessment, including claims analysis and payer research. The interim findings, along with the full data expected later in 2027, will guide the plans and design of our phase III registration program.

Donn CasalePresident and CEO

ARS-2 could add meaningful platform value as potential first FDA-approved on-demand treatment for breakthrough flares in CSU, including in patients on biologics. Importantly, this is an indication we could commercialize efficiently and effectively using the same sales force we have for neffy today. If we execute on each of these objectives, I believe we can create a meaningful value for our stakeholders over both the near and long term. To get there, we have brought in multiple senior leaders with proven track records. We recently appointed Dr. Randall Kaye as Chief Medical Officer. Randall is an allergist and an immunologist with more than 30 years in medicine. We also recently appointed John Slebir as Chief Legal Officer, bringing expertise across business operations, strategic and financial transactions, and corporate governance. In August, Meg Smith joined us as Chief Commercial Officer.

Donn CasalePresident and CEO

Meg is a commercial expert with a record of winning in prevention-type markets. She knows how to lead teams that drive behavior change. With that, let me turn the call over to Meg for a commercial update.

Meg SmithChief Commercial Officer

Thanks, Don, and good afternoon, everyone. I am honored to be leading the commercial team as we enter the next phase of commercialization for neffy. What I have seen in my first two months confirms that neffy is a meaningful advance in a market where patients need a better solution. neffy competes in an existing market of more than 5 million U.S. prescriptions annually, almost all of which are needle-based auto-injectors. Only about one in three patients with an auto-injector prescription carry it consistently, and roughly half delay or never use it during a reaction. This is an unacceptable gap, leaving patients unprepared and unprotected. A needle-free, easy-to-carry, and easy-to-administer device can close that protection gap and expand the market over time. When you launch a product into an entrenched market where prescriber behavior has been the same for decades, product attributes alone are not enough to change behavior.

Meg SmithChief Commercial Officer

That is why my priority was to build a commercial strategy focused on changing this long-standing provider behavior, and then to align every function behind it. Our commercial strategy aims to deliver steady year-over-year market share gains through targeted provider engagement, growing share in the existing market today. Our commercial approach is built around three key areas of focus: where we engage, what we say, and how we convert a prescription into a fill consistently. First, where we engage. We are moving to an account-based approach to sales targeting. Our highest-value prescribers often sit with other advanced practice providers, nurses, and office staff, all of whom influence whether a prescription is written and filled. That includes the staff who handle electronic prescriptions, refill protocols, and prior authorizations, as well as those who counsel patients and caregivers, all of which are incredibly important considerations in the epinephrine market.

Meg SmithChief Commercial Officer

Calling on an account rather than a single provider means one visit reaches the entire care team. That makes our engagement more effective at changing these entrenched prescribing habits and office protocols, and also allows our sales representatives to be more efficient. Second is what we say. For decades, the auto-injector has been the default because there was no alternative. We are reframing the conversation with providers around what happens after the prescription for an auto-injector is written, or more specifically, what doesn't happen. What we need to do is not only drive awareness of the problem that exists in the epinephrine market, but also an appreciation for the role that the physician plays in the prescribing decision. A patient can advocate for themselves, but ultimately, the decision on a prescription sits with the trusted healthcare provider.

Meg SmithChief Commercial Officer

Once a physician embraces that there is a problem and assumes responsibility for addressing that problem, neffy becomes the obvious solution. To anchor this work, we are developing a bold new marketing campaign that we expect to roll out in early 2027. Turning to the third area, how we convert. Once a prescription is written, our team needs to support that prescription all the way through to fulfillment. Today, prior authorization is where we lose the most conversion from prescription to fill, and where we can improve the fastest. Prior authorizations are routine in allergy practices, including for the biologics these same physicians prescribe regularly. Because our representatives now engage the full care team, including the staff who manage PA submissions, we can make sure those offices have what they need to complete them. When they do, the majority of submitted PAs are approved.

Meg SmithChief Commercial Officer

Importantly, every PA submitted also builds documented demand with payers, which strengthens our case for broader coverage. Under new market access leadership, our team is executing a payer engagement approach focused on opening the remaining Medicaid states and expanding access across all commercial plans. These initiatives and others are geared towards establishing neffy as a standard of care and ensuring that every prescription becomes a filled prescription so that patients have effective protection when they need it. ARS has a tremendous opportunity to reshape this market. Applying fresh thinking to entrenched markets is what I've done throughout my career. We now have a single commercial strategy that drives every decision, a disciplined investment approach that ties every dollar back to it, and a talented, passionate team to execute.

Meg SmithChief Commercial Officer

It will take time, but I firmly believe the opportunity is within our reach, and I look forward to sharing our progress in the coming quarters. I'll now pass the call to Kathy to review our financials.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day